Hematopoietic SCT from Partially HLA-mismatched (HLA-haploidentical) Related Donors

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2008 Aug 6

PMID 18679375

Citations 15

Authors

H J Symons

E J Fuchs

Affiliations

Soon will be listed here.

Abstract

Hematopoietic SCT from a partially HLA-mismatched (HLA-haploidentical) first-degree relative offers the benefits of rapid and near universal donor availability but also the risks that result from traversing the HLA barrier; namely, graft failure, severe GVHD and prolonged immunodeficiency. Improvements over the last 10 years in conditioning regimens, graft engineering and pharmacological immunoprophylaxis of GVHD have substantially reduced the morbidity and mortality of HLA-haploidentical SCT. Highly immunosuppressive but nonmyeloablative conditioning extends the availability of HLA-haploidentical SCT to elderly hematologic malignancy patients lacking HLA-matched donors and permits recovery of autologous hematopoiesis in the event of graft failure. Current regimens for HLA-haploidentical SCT are associated with a 2-year non-relapse mortality of 20+/-5%, relapse of 35+/-15% and overall survival of 50+/-20%. Major developmental areas include harnessing natural killer cell alloreactivity to reduce the risk of disease relapse and improving immune reconstitution by delayed infusions of lymphocytes selectively depleted of alloreactive cells. Hematologic malignancy patients who lack suitably matched related or unrelated donors can now be treated with HLA-haploidentical related donor or unrelated umbilical cord blood SCT. Future clinical trials will assess the relative risks and benefits of these two graft sources.

Citing Articles

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.

Reina-Ortiz C, Giraldos D, Azaceta G, Palomera L, Marzo I, Naval J Cells. 2022; 11(3).

PMID: 35159200 PMC: 8834301. DOI: 10.3390/cells11030392.

Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Rangarajan H, Pereira M, Brazauskas R, Martin A, Kussman A, Elmas E Transplant Cell Ther. 2021; 27(11):926.e1-926.e10.

PMID: 34407489 PMC: 8574163. DOI: 10.1016/j.jtct.2021.08.009.

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Calvo T, Reina-Ortiz C, Giraldos D, Gascon M, Woods D, Asenjo J Sci Rep. 2020; 10(1):19398.

PMID: 33173077 PMC: 7655821. DOI: 10.1038/s41598-020-76051-z.

Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults.

Barban J, Simoes B, Moraes B, Anunciacao C, Rocha C, Pintor D Einstein (Sao Paulo). 2020; 18:AE4530.

PMID: 32049129 PMC: 6999189. DOI: 10.31744/einstein_journal/2020AE4530.

Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation.

Ricci A, Jin Z, Broglie L, Bhatia M, George D, Garvin J Bone Marrow Transplant. 2019; 55(2):384-392.

PMID: 31537901 DOI: 10.1038/s41409-019-0688-9.

References

OReilly R, Keever C, Kernan N, Brochstein J, Collins N, Flomenberg N . HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc. 1987; 19(6 Suppl 7):55-60. View

Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H . Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81(10):1390-7. DOI: 10.1097/01.tp.0000214462.63943.14. View

Nguyen S, Kuentz M, Vernant J, Dhedin N, Bories D, Debre P . Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia. 2007; 22(2):344-52. DOI: 10.1038/sj.leu.2405041. View

Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8):3051-7. DOI: 10.1182/blood-2004-07-2974. View

Mavroudis D, Jiang Y, Hensel N, Lewalle P, Couriel D, Kreitman R . Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant. 1996; 17(5):793-9. View

Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S . Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001; 97(8):2514-21. DOI: 10.1182/blood.v97.8.2514. View

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Giralt S, Logan B, Rizzo D, Zhang M, Ballen K, Emmanouilides C . Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007; 13(7):844-52. DOI: 10.1016/j.bbmt.2007.03.011. View

Ge X, Brown J, Sykes M, Boussiotis V . CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant. 2008; 14(5):518-30. PMC: 2423190. DOI: 10.1016/j.bbmt.2008.02.010. View

10.

Ballen K, Spitzer T, Yeap B, McAfee S, Dey B, Attar E . Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007; 13(1):82-9. PMC: 2947324. DOI: 10.1016/j.bbmt.2006.08.041. View

11.

Beilhack A, Schulz S, Baker J, Beilhack G, Wieland C, Herman E . In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005; 106(3):1113-22. PMC: 1895168. DOI: 10.1182/blood-2005-02-0509. View

12.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

13.

Chen B, Cui X, Sempowski G, Liu C, Chao N . Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood. 2003; 103(4):1534-41. DOI: 10.1182/blood-2003-08-2987. View

14.

Dong L, Wu T, Zhang M, Gao Z, Lu D . CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant. 2007; 13(12):1515-24. DOI: 10.1016/j.bbmt.2007.09.007. View

15.

Beatty P . The immunogenetics of bone marrow transplantation. Transfus Med Rev. 1994; 8(1):45-58. DOI: 10.1016/s0887-7963(94)70097-3. View

16.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

17.

Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007; 92(3):414-7. DOI: 10.3324/haematol.10570. View

18.

Montagna D, Yvon E, Calcaterra V, Comoli P, Locatelli F, Maccario R . Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999; 93(10):3550-7. View

19.

Brunstein C, Barker J, Weisdorf D, DeFor T, Miller J, Blazar B . Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007; 110(8):3064-70. PMC: 2018678. DOI: 10.1182/blood-2007-04-067215. View

20.

Barker J, Krepski T, DeFor T, Davies S, Wagner J, Weisdorf D . Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002; 8(5):257-60. DOI: 10.1053/bbmt.2002.v8.pm12064362. View